KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences
May 20 2019 - 7:30AM
Business Wire
– Phase 1 Data on Oral Plasma Kallikrein
Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks
to be Presented –
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, announced
that data has been accepted for presentation at both the C1
Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary
and European Academy of Allergy and Clinical Immunology (EAACI)
Congress in Lisbon, Portugal.
“We are excited to present more Phase 1 data on KVD900, our oral
plasma kallikrein inhibitor in development for on-demand treatment
of hereditary angioedema, or HAE,” said Andrew Crockett, Chief
Executive Officer of KalVista. “Our Phase 2 clinical trial of
KVD900 is still expected to have data late this year. We remain
committed to providing options for patients to manage their disease
with oral medicines.”
C1 Inhibitor Workshop Presentations:
- KVD900, a new oral on-demand
treatment of hereditary angioedema attacks achieves complete plasma
kallikrein suppression: safety, tolerability, pharmacokinetic and
pharmacodynamic results from a phase 1 first-in-human
studySaturday, May 25, 2019 from 11:00-12:30 CEST, Oral 25
- High plasma exposures of KVD900
achieved in First in Human study markedly inhibit plasma
prekallikrein activation; early blockade of plasma kallikrein (PKa)
may halt attacks in hereditary angioedema (HAE) by reducing contact
system activationSaturday, May 25, 2019 from 2:30-4:00 pm CEST,
Poster 35
EAACI Poster:
- Rapid and Nearly Complete
Suppression of Plasma Kallikrein Activity with the Oral Inhibitor
KVD900: Results of a Phase 1 Study Evaluating KVD900’s Potential as
a Treatment for Acute Attacks of HAE Tuesday, June 4, 2019
from 10:30-12:00 pm WESTPDS #21, Mediators in anaphylaxis and
angioedema, Zone B
About KalVista Pharmaceuticals, Inc.KalVista
Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development, and commercialization of small molecule
protease inhibitors for diseases with significant unmet need. The
initial focus is on inhibitors of plasma kallikrein, which is an
important component of the body’s inflammatory response and which,
in excess, can lead to increased vascular permeability, edema and
inflammation. KalVista has developed a proprietary portfolio of
novel, small molecule plasma kallikrein inhibitors initially
targeting hereditary angioedema (HAE) and diabetic macular edema
(DME). The Company has created a structurally diverse portfolio of
oral plasma kallikrein inhibitors and is advancing multiple drug
candidates for HAE as well as DME. The Company has selected KVD900
as its program to be advanced as an on-demand therapy for HAE
attacks and commenced a Phase 2 proof-of-concept study in HAE
patients in late 2018. In DME, KalVista’s most advanced program, an
intravitreally administered plasma kallikrein inhibitor known as
KVD001, began a Phase 2 clinical trial in 2017 that is anticipated
to complete in the second half of 2019.
For more information, please visit www.kalvista.com.
Forward-Looking StatementsThis press release contains
"forward-looking" statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "goal," "seek," "believe,"
"project," "estimate," "expect," "strategy," "future," "likely,"
"may," "should," "will" and similar references to future periods.
These statements are subject to numerous risks and uncertainties
that could cause actual results to differ materially from what we
expect. Examples of forward-looking statements include, among
others, available funding, our cash runway and future clinical
trial timing and results. Further information on potential risk
factors that could affect our business and its financial results
are detailed in the annual report on Form 10-K filed on July 30,
2018 and other reports as filed from time to time with
the Securities and Exchange Commission. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190520005168/en/
KalVista Pharmaceuticals, Inc.Leah MonteiroDirector,
Corporate Communications & Investor
Relations857-999-0808leah.monteiro@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Mar 2024 to Apr 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2023 to Apr 2024